Cadrenal Therapeutics, Inc. [CVKD]

Source: 

Company Overview

Cadrenal Therapeutics, Inc. is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation, or AFib.